Aptamer Group (LSE:APTA) has begun a new development programme to create Optimer binders for a rapid diagnostic test targeting the Bundibugyo strain of the Ebola virus, following the largest recorded outbreak affecting the Democratic Republic of Congo and Uganda. The project is intended to address a significant diagnostic gap, as current antibody-based tests have limited sensitivity for this strain, which differs biologically from the more widespread Zaire variant and carries a fatality rate of between 30% and 50%.
The company plans to develop binders suitable for use in rapid, field-deployable diagnostic tests by building on its previous experience during the COVID-19 pandemic, when its SARS-CoV-2 Optimer binders were successfully incorporated into lateral flow assays. With demand for Ebola testing expected to increase as governments and healthcare organisations strengthen outbreak preparedness, Aptamer believes the programme could expand its presence in the infectious disease diagnostics market while contributing to efforts to improve disease detection during the current outbreak.
Despite the strategic opportunity, Aptamer’s investment outlook continues to be weighed down by weak financial performance, including sharply lower revenue, ongoing losses and negative cash flow. Technical indicators also remain negative, with the shares trading below key moving averages, while a negative price-to-earnings ratio and the absence of dividend support continue to limit valuation.
More about Aptamer Group plc
Aptamer Group plc is an AIM-listed biotechnology company focused on developing synthetic molecular binders for life sciences applications. Its proprietary Optimer platform enables the creation of highly specific binding molecules that can be integrated into diagnostic, therapeutic and research products. The company’s technology is increasingly being applied to rapid infectious disease testing, positioning Aptamer to support global healthcare preparedness and emerging diagnostic markets.
Leave a Reply